| 查看: 876 | 回复: 7 | ||||
[交流]
STM：靶向作用脂肪激素或可开发出治疗2型糖尿病的新型疗法
|
||||
|
12月23日，来自哈佛大学的一个研究团队通过研究描述了一种临床前的方法或可帮助治疗2型糖尿病、脂肪肝及其它代谢性疾病，文章中研究者开发了一种抗体，其可以改善通过靶向作用脂肪组织中名为aP2（FABP4）的激素来帮助改善机体的葡萄糖调节，并且降低肥胖小鼠集体的脂肪肝症状。 Development of a therapeutic monoclonal antibody that targets secreted fatty acid–binding protein aP2 to treat type 2 diabetes http://stm.sciencemag.org/content/7/319/319ra205 Kill the messenger A variety of metabolic messengers—many from adipose tissue itself—controls the energy state of organs and organisms. Recently, researchers showed that the fatty acid binding protein aP2, once thought to live and work only in the cytoplasm, is also secreted by adipose tissue and spurs metabolic changes in other organs. Now, Burak and colleagues test whether secreted aP2 can serve as a therapeutic target for type 2 diabetes. In mice, the secreted form of aP2 regulates glucose production in liver, systemic glucose homeostasis, and insulin resistance. Serum levels of aP2 were shown to be elevated in obese mice and humans and to correlate with metabolic complications. The authors identified a monoclonal antibody to aP2 that lowered fasting blood glucose, increased insulin sensitivity, and lowered both fat mass and fatty liver (steatosis) in obese mouse models, relative to a control antibody, but not in aP2-deficient mice. The antidiabetic effects of the therapeutic antibody were linked to the regulation of hepatic glucose output and peripheral glucose utilization. Together, these findings suggest that an aP2-targeted antibody that kills the messenger is a viable approach for diabetes treatment. Abstract The lipid chaperone aP2/FABP4 has been implicated in the pathology of many immunometabolic diseases, including diabetes in humans, but aP2 has not yet been targeted for therapeutic applications. aP2 is not only an intracellular protein but also an active adipokine that contributes to hyperglycemia by promoting hepatic gluconeogenesis and interfering with peripheral insulin action. Serum aP2 levels are markedly elevated in mouse and human obesity and strongly correlate with metabolic complications. These observations raise the possibility of a new strategy to treat metabolic disease by targeting serum aP2 with a monoclonal antibody (mAb) to aP2. We evaluated mAbs to aP2 and identified one, CA33, that lowered fasting blood glucose, improved systemic glucose metabolism, increased systemic insulin sensitivity, and reduced fat mass and liver steatosis in obese mouse models. We examined the structure of the aP2-CA33 complex and resolved the target epitope by crystallographic studies in comparison to another mAb that lacked efficacy in vivo. In hyperinsulinemic-euglycemic clamp studies, we found that the antidiabetic effect of CA33 was predominantly linked to the regulation of hepatic glucose output and peripheral glucose utilization. The antibody had no effect in aP2-deficient mice, demonstrating its target specificity. We conclude that an aP2 mAb–mediated therapeutic constitutes a feasible approach for the treatment of diabetes. |
回复此楼» 收录本帖的淘帖专辑推荐
 新药资讯 |
» 猜你喜欢
三年实验室工作经历，一志愿华中农业大学微生物，总分288求调剂
已经有5人回复
-
070700求调剂
已经有1人回复
-
药理学论文润色/翻译怎么收费?
已经有200人回复
-
求调剂总分327
已经有1人回复
-
BL21(DE3)UV或者丝裂霉素诱导条件下会释放DE3的噬菌体吗？
已经有479人回复
-
NSCLC脑转移肿瘤模型
已经有0人回复
-
CHP-134这个细胞系哪里有？
已经有0人回复
-
27年环评考试资料
已经有1人回复
-
多糖提取纯化结构表征和活性
已经有0人回复
-
英国贝尔法斯特女王大学药物递送方向招CSC博士生
已经有1人回复
» 抢金币啦！回帖就可以得到:
-
讨论一下
+1/293
-
27博士申请
+1/181
-
大连理工大学化工学院郑跃楠副教授计划招收2027级博士研究生
+1/176
-
南开大学罗景山教授课题组招收2027年入学博士生
+2/142
-
科研涂膜制样 HK‑5000AZ 真空型实验室小型涂布试验机｜线棒 / 刮刀双模式
+1/94
-
招收2027级 博士生（湘潭大学 非均相催化 相关方向）
+1/90
-
山东省寄生虫病防治研究所尹昆课题组招收2027级博士研究生
+1/87
-
慢蹲一个与子偕老的爱人
+1/46
-
海南大学化学化工学院姜忠义膜科学与膜技术团队2027年第一批博士招生
+1/41
-
涂层低温高湿（雨淞覆冰）测试
+1/36
-
慢蹲一个与子偕老的爱人
+1/36
-
哈尔滨工程大学 · 先进核动力装置课题组 · 2027年博士招生
+1/22
-
中科院大连化物所张涛院士团队诚聘优秀博士后人才
+1/9
-
西南交通大学李义兵课题组博士及青年英才招聘
+1/7
-
福建师范大学招收2027年博士研究生（申请考核）
+1/6
-
中科院大连化物所张涛院士团队诚聘优秀博士后人才
+1/6
-
西南交通大学李义兵课题组博士及青年英才招聘
+1/5
-
欢迎报考香港城市大学化学系博士课程 (HKPFS/常规PhD)
+1/5
-
吉林大学闫旭教授（国家级青年人才）招收2027级博士研究生
+1/5
-
中科院东莞材料所新能源材料研究部招聘研究员/副研究员（中央事业编制）
+1/5
8楼2016-01-10 22:43:00
简单回复
jiantu2楼
2015-12-29 10:32
回复
linglingchen(金币+1): 谢谢参与
liangbk3楼
2015-12-29 11:05
回复
linglingchen(金币+1): 谢谢参与
tzynew4楼
2015-12-29 12:50
回复
linglingchen(金币+1): 谢谢参与
假大空5楼
2015-12-29 13:24
回复
linglingchen(金币+1): 谢谢参与
2015-12-29 13:42
回复
linglingchen(金币+1): 谢谢参与
好
2016-01-09 22:32
回复
1
